Alpha-1-proteinase inhibitor
- Generic Name
- Alpha-1-proteinase inhibitor
- Brand Names
- Aralast, Glassia, Prolastin, Prolastin-C, Respreeza, Zemaira
- Drug Type
- Biotech
- CAS Number
- 9041-92-3
- Unique Ingredient Identifier
- F43I396OIS
- Background
Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.
- Indication
For chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
- Associated Conditions
- Emphysema
- Associated Therapies
- Augmentation, Maintenance therapy
Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant
- Conditions
- Kidney TransplantType 1 Diabetes
- Interventions
- Procedure: Islet Transplantation
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT02464878
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery
- Conditions
- Post Cardiac Surgery Systemic Inflammatory Response
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Soroka University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT02191839
Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses
- Conditions
- Neuromyelitis Optica
- Interventions
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Stanford University
- Registration Number
- NCT02087813
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Alpha1 Antitrypsin Aerosol Therapy in Cystic Fibrosis
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- Université de Sherbrooke
- Target Recruit Count
- 17
- Registration Number
- NCT02010411
- Locations
- 🇨🇦
Centre de Recherche du CHUS, Sherbrooke, Quebec, Canada
Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction
- First Posted Date
- 2013-09-06
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 10
- Registration Number
- NCT01936896
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT01700036
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.
- Conditions
- Alpha 1 Antitrypsin Deficiency
- Interventions
- First Posted Date
- 2012-08-21
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Michael Campos, MD
- Target Recruit Count
- 10
- Registration Number
- NCT01669421
- Locations
- 🇺🇸
Division of Pulmonary and Critical Care, Human Reseach, U of Miami, Miami, Florida, United States
A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
Efficacy of a Naturally-derived Mouthrinse for Gingival Inflammation
- Conditions
- Gingivitis
- Interventions
- First Posted Date
- 2009-04-22
- Last Posted Date
- 2012-07-17
- Lead Sponsor
- Shaare Zedek Medical Center
- Target Recruit Count
- 94
- Registration Number
- NCT00885599
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- BPGbio
- Target Recruit Count
- 35
- Registration Number
- NCT00652080
- Locations
- 🇺🇸
Burke Pharmaceuticals, Hot Springs, Arkansas, United States
🇺🇸Skin Surgery Medical Group, Inc., San Diego, California, United States
🇺🇸Glazer Dermatology, Buffalo Grove, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.